In order to examine the intensity and overall expression of the receptor tyrosine kinase MET in primary hormone receptor positive luminal-type mammary carcinoma, MET expression was analyzed by applying a semi-quantitative immunoreactivity scoring (IRS) system on a tissue-microarray, as described previously [42] (see clinicopathologic parameters of the study group in Table 1 and Materials and Methods for detailed methodology). The gene discussed is NR4A1; the disease is breast carcinoma.